Chris Mason

Ori Biotech is a London and New Jersey-based technology company focused on revolutionizing the manufacturing of cell and gene therapies (CGT). The company has developed a proprietary, fully automated, and closed manufacturing platform designed to enable therapeutic developers to scale from preclinical process development to commercial manufacturing seamlessly. By standardizing and automating complex biological processes, Ori aims to increase throughput, improve product quality, and significantly reduce costs, thereby expanding patient access to life-saving personalized medicines. The company operates as a technology partner to biotech and pharma companies rather than a drug developer itself.